Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VIR vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: VIR 3 – 3 XOMA Matrix Metrics: VIR 4 – 6 XOMA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Vir Biotechnology, Inc. (VIR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VIR carries a Unified Composite Score of 41.6/100 (SELL) at $9.71 (4.3x Forward P/E, -70.2% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. VIR 41.6/100 SELL) and 0.68β · 37% Vol risk profile, whereas VIR leads top-line expansion (+19582.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VIR is currently in a Breakdown options structure phase (RSI 39.6); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIR vs XOMA
VIR NASDAQ
Vir Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.71
-2.46% 1D
Market Cap $2.1B
TTM Revenue $303M
Forward P/E 4.3x
Beta / 30D Vol 1.72β · 102% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 20.0 Fund 46.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.6 · SMA20: $11.44 · SMA50: $11.11
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (VIR 3 – 3 XOMA)

Columns: Metric · VIR · XOMA
1. Valuation Multiples VIR
Forward P/E 4.3x 21.5x
Trailing P/E 4.3x 28.2x
PEG Ratio N/M N/M
EV / Revenue 6.4x 16.1x
2. Growth & Scale VIR
Revenue Growth (YoY) +19582.5% -22.6%
Earnings Growth (YoY) +58.5% +207.9%
TTM Revenue (USD) $303M $49M
Market Cap $2.1B $781.8M
3. Profitability & Quality XOMA
Gross Margin -36.7% 99.0%
Operating Margin -70.2% -3.9%
Net Profit Margin -61.0% 69.6%
Return on Equity (ROE) -21.8% 34.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) -$142M $8.3M EBITDA
Cash Flow Margin -46.8% 17.1% EBITDA Mgn
Net Cash / Leverage $128M Net Cash $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XOMA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 69.6% (6th %ile) 101.5% (100th %ile)
Put/Call OI Skew 0.20x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat VIR
OpEx & R&D Intensity 33.5% of Rev ($101M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIR (4) vs XOMA (6)
Institutional Metric VIR XOMA Criterion Row Edge
Market Capitalization
Scale
$2.1B $781.8M Larger Scale VIR
Trailing P/E Ratio
Valuation
4.3x 28.2x Lower Multiple VIR
Forward P/E Ratio
Valuation
4.3x 21.5x Lower Multiple VIR
Revenue Growth (YoY)
Growth
+19582.5% -22.6% Higher Growth VIR
Operating Margin (TTM)
Profitability
-70.2% -3.9% Higher Margin XOMA
Net Profit Margin
Profitability
-61.0% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
-21.8% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
48% ($5–$14) 78% ($22–$45) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
1.72β · 102% Vol 0.68β · 37% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
41.6 / 100 (SELL) 55.8 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$303M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-36.7% 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$142M ($128M Net Cash) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIR +21.63 pp
VIR: +17.82% · XOMA: -3.81%
3M Horizon XOMA +7.02 pp
VIR: +2.32% · XOMA: +9.34%
6M Horizon VIR +29.1 pp
VIR: +63.36% · XOMA: +34.26%
1Y Horizon VIR +53.1 pp
VIR: +77.7% · XOMA: +24.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIR vs XOMA. Trailing 12-month operating profitability (VIR -70.2% vs XOMA -3.9%) and valuation multiples (VIR 4.3x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

VIR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$303M
Gross Margin-36.7%
Op. Margin-70.2%
ROE / Fwd P/E-21.8% · 4.3x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIR BREAKDOWN
5d in phase · OBV DISTRIBUTION
Current IV 69.6%
IV Percentile 6th %ile
Put/Call OI Skew 0.20x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact VIR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -70.2% operating margin.
OpEx & R&D Reinvestment 33.5% of Rev ($101M)
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VIR vs XOMA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Vir Biotechnology, Inc. (VIR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VIR carries a Unified Composite Score of 41.6/100 (SELL) at $9.71 (4.3x Forward P/E, -70.2% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. VIR 41.6/100 SELL) and 0.68β · 37% Vol risk profile, whereas VIR leads top-line expansion (+19582.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VIR is currently in a Breakdown options structure phase (RSI 39.6); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VIR leads the Growth & Scale pillar: VIR posts +19582.5% YoY revenue growth and +58.5% YoY earnings growth on $303M TTM revenue (-36.7% gross margin, -70.2% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, VIR generates $303M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, VIR deploys 33.5% of Rev ($101M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

VIR screens cheaper on headline valuation multiples. VIR trades at 4.3x Forward P/E, 4.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-46.8% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIR (-21.8% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VIR carries 69.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.72β · 102% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.